MAP2K7 and cancer: Inhibition of SOS1 can increase the chemosensitivity of KRAS-amplified cancer cells to MEK inhibition and the SOS1 inhibitor BI-3406 has been demonstrated to synergize with the MEK inhibitor trametinib [21, 29].